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Summ a r y
Among the survivors of Ebola virus disease (EVD), complications that include 
uveitis can develop during convalescence, although the incidence and pathogenesis 
of EVD-associated uveitis are unknown. We describe a patient who recovered from 
EVD and was subsequently found to have severe unilateral uveitis during convales-
cence. Viable Zaire ebolavirus (EBOV) was detected in aqueous humor 14 weeks after 
the onset of EVD and 9 weeks after the clearance of viremia.
The current outbreak of EVD is believed to have begun in Decem-ber 2013.1 As of April 26, 2015, a total of 26,312 cases of EVD (including 10,899 deaths) had been reported in six countries in West Africa (i.e., Sierra 
Leone, Liberia, Guinea, Mali, Nigeria, and Senegal), the United States, the United 
Kingdom, and Spain.2 The outbreak has also resulted in the largest number of EVD 
survivors in history.
Among survivors of EVD, late complications that include ocular disease can 
develop during convalescence.3,4 However, few systematic studies have been con-
ducted on post-EVD sequelae, so the incidence and clinical manifestations of post-
EVD ocular complications are unclear. Here, we report the clinical course of a man 
in whom severe, acute, unilateral uveitis developed during the convalescent phase 
of EVD. We also report the detection of viable EBOV in aqueous humor obtained 
from the inflamed eye 14 weeks after the onset of the initial symptoms of EVD 
and 9 weeks after the clearance of viremia.
C a se R eport
A previously healthy 43-year-old male physician received a diagnosis of EVD on 
September 6, 2014, while he was working in an Ebola treatment unit in Kenema, 
Sierra Leone. He was transferred to Emory University Hospital in Atlanta and ar-
rived 4 days after the onset of symptoms. He was treated with an experimental 
small interfering RNA antiviral agent (TKM-100802, Tekmira Pharmaceuticals), 
convalescent plasma, and aggressive supportive care.5
The hospital course was complicated by multiorgan system failure requiring 
mechanical ventilation for 12 days and hemodialysis for 24 days.6 After extubation, 
the patient had altered mental status, difficulty walking related to severe proximal 
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weakness and deconditioning, and extreme fa-
tigue. On day 44 of the illness, hemodialysis was 
no longer required and his mental status had 
markedly improved, with some residual mild 
word-finding difficulty. Ambulation was limited 
to short distances because of exertional fatigue. 
Blood and urine tested negative for EBOV on 
quantitative reverse-transcriptase–polymerase-
chain-reaction (RT-PCR) assay on serial speci-
mens, and he was discharged home. A semen 
sample obtained on the day of discharge was 
positive for EBOV RNA on quantitative RT-PCR 
assay, and EBOV was isolated from semen by 
means of culture at the Centers for Disease Con-
trol and Prevention (CDC).7 The patient was ad-
vised to abstain from sex or to use condoms for 
at least 3 months.8 Longitudinal monitoring of 
semen specimens for EBOV is ongoing.
After discharge, 10 weeks after the onset of 
EVD symptoms, the patient’s word-finding dif-
ficulty and exercise tolerance were markedly 
improved, but he had new symptoms, including 
low back pain involving the right lumbar and 
sacroiliac region, bilateral enthesitis of the 
Achilles’ tendon, and paresthesias involving the 
distal lower limbs. Ophthalmic symptoms, which 
began shortly after discharge from the hospital, 
included occasional bilateral ocular burning, 
foreign-body sensation, and photophobia. He 
required an adjustment in his prescription for 
reading glasses, which suggested an accommo-
dative change. His ocular history was clinically 
significant only for myopia. He was referred to 
the Emory Eye Center for further evaluation.
On initial evaluation in November 2014, the 
patient’s visual acuity was 20/15 bilaterally while 
wearing eyeglasses. Intraocular pressure, pupils, 
ocular motility, and confrontational visual fields 
were normal. The examination of the anterior 
eye by means of slit lamp was normal. The exam-
ination of the dilated posterior eye revealed 
previously undocumented multiple, peripheral 
chorioretinal scars with hypopigmented halos in 
both eyes and a small intraretinal hemorrhage 
adjacent to one scar in the left eye (Fig. 1). He 
received the diagnosis of posterior uveitis (i.e., 
chorioretinitis), a likely sequela of EVD. Close 
clinical follow-up was planned.
One month later, 14 weeks after the diagnosis 
of EVD, he presented with an acute onset of red-
ness, blurred vision with halos, pain, and photo-
phobia in the left eye. Visual acuity was mea-
sured at 20/15 in the right eye and 20/20 in the 
left eye. The left intraocular pressure was highly 
elevated at 44 mm Hg (normal value, 10 to 21). 
Slit-lamp examination of the left eye showed 
conjunctival injection, mild corneal edema, rare 
nongranulomatous keratic precipitates, and grade 
1+ leukocytes and protein (flare) in the anterior 
chamber (Fig. 2). Examination of the anterior 
Figure 1. Montage Fundus Photographs 10 Weeks after the Onset of Ebola Virus Disease.
Multiple peripheral chorioretinal scars with hypopigmented haloes are visible in the right eye (Panel A) and left eye 
(Panel B) (white arrows). A small intraretinal hemorrhage (black arrow) is adjacent to a chorioretinal scar in the left eye.
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chamber with gonioscopy indicated no signs of 
angle closure. Dilated funduscopic examination 
showed stable chorioretinal scars in both eyes 
with no other signs of ocular inflammation. He 
received a diagnosis of anterior uveitis and ocu-
lar hypertension in the left eye. Treatment was 
started with eyedrops containing 1% predniso-
lone acetate four times daily and with ocular 
hypotensive agents including acetazolamide (at a 
dose of 500 mg orally twice daily), eyedrops 
containing 0.2% brimonidine twice daily, and 
eyedrops containing 2% dorzolamide and 0.5% 
timolol twice daily. Results of laboratory testing, 
including measurement of the erythrocyte sedi-
mentation rate and C-reactive protein, were 
normal; rapid plasma reagin testing and sero-
logic analysis for Toxoplasma gondii were negative.
Because of escalating anterior-chamber in-
flammation and worsening symptoms during 
the subsequent 48 hours, the frequency of ad-
ministration of prednisolone acetate was in-
creased to every 2 hours, and eyedrops contain-
ing 1% atropine twice daily were added. After 
another 24 hours of increasing inflammation 
and concern about an infectious cause, paracen-
tesis of the anterior chamber was performed, 
with aspiration of 170 μl of aqueous humor 
through a sterile 30-gauge needle while the prac-
titioner was wearing gloves and a surgical mask. 
The specimen was double-bagged and delivered 
to a dedicated laboratory at Emory University 
Hospital for testing samples from patients with 
EVD. Testing was performed by clinical labora-
tory technologists who were trained in the safe 
handling of infectious pathogens and with the 
use of the standard institutional operating pro-
tocols.9 The aqueous humor tested positive for 
EBOV RNA on quantitative RT-PCR assay, with a 
cycle threshold value of 18.7. EBOV was isolated 
from this specimen by means of a viral culture 
performed at the CDC.7 A conjunctival swab ob-
tained before the procedure and tear-film speci-
mens collected before the procedure and 24 hours 
after the procedure tested negative for EBOV RNA 
on quantitative RT-PCR assay. In addition, a 
specimen of peripheral blood tested negative for 
EBOV RNA on quantitative RT-PCR assay. Pre-
liminary analyses of EBOV sequenced from blood 
during the patient’s hospitalization for symptom-
atic EVD, as compared with EBOV sequenced 
from ocular fluid, identified a single nonsynony-
mous mutation, as well as two silent mutations 
and two mutations in noncoding regions. The 
significance of these mutations is unknown. 
However, these findings are in contrast to re-
sults that showed no changes in viral consensus 
sequences acquired over several days from a 
single patient.10 All personal protective equip-
ment and materials that were used during para-
centesis and laboratory testing were sterilized by 
means of autoclaving before disposal.11
The uveitis continued to progress; by 5 days 
after the onset of symptoms, visual acuity in the 
left eye was decreased to 20/60. Anterior-seg-
ment examination revealed scleritis and persis-
tent anterior uveitis. Intermediate uveitis (i.e., 
vitritis, with grade 0.5+ haze) was noted on ex-
amination of the dilated posterior segment. Oral 
prednisone (at a dose of 1 mg per kilogram of 
body weight per day) was started. Ophthalmic 
drops of 1% prednisolone acetate every 2 hours, 
0.5% timolol twice daily, and 1% atropine twice 
daily were continued in the left eye.
During the subsequent 72 hours, the patient’s 
condition improved, with resolution of the scle-
ritis and a decrease in the anterior uveitis. De-
spite this improvement in the anterior-segment 
inflammation, the vitritis worsened, resulting in 
a decrease in visual acuity to 20/400 in the left 
eye at 1 week (Fig. 3). Continued clinical deterio-
ration of the patient’s left eye prompted the ini-
tiation of treatment with topical difluprednate 
(Alcon Laboratories), a 21-day course of oral 
favi piravir (MediVector), a periocular injection of 
Figure 2. Slit-Lamp Photograph of the Left Eye 14 
Weeks after the Onset of Ebola Virus Disease.
Mild corneal edema, rare keratic precipitates (arrows), 
and inflammatory cells and protein in the anterior 
chamber are consistent with acute anterior uveitis.
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triamcinolone, and a 10-week tapering course of 
oral prednisone. On examination 3 months after 
presentation with uveitis, the vitritis was resolv-
ing and left visual acuity had recovered to 20/15. 
Follow-up ophthalmic evaluations are ongoing.
Discussion
We describe the detection of viable EBOV in the 
aqueous humor of the eye in a patient in recov-
ery from EVD with acute panuveitis (a combi-
nation of anterior, intermediate, and posterior 
uveitis). In a previous EVD outbreak, EBOV RNA 
was detected on RT-PCR assay in a conjunctival 
sample obtained from a 25-year-old patient 22 
days after the onset of symptoms and 10 days 
after viremia had cleared. In that patient, 45 days 
after the onset of EVD symptoms, posterior uve-
itis developed; the patient did not undergo any 
additional testing of ocular tissue.4 Marburg vi-
rus, a filovirus like EBOV, has also been associ-
ated with uveitis during convalescence. In 1975, 
Marburg virus was cultured from the aqueous 
humor of a patient with acute anterior uveitis 
that developed nearly 3 months after the onset 
of acute illness.12 Viral culture of the patient’s 
aqueous humor that was sampled 2 weeks later 
was negative.13
Although the pathogenesis of EVD-associated 
uveitis is unknown, we believe that the severe, 
acute panuveitis that developed in our patient 
was a direct cytopathic effect of active replica-
tion of EBOV persisting in an immune-privileged 
organ. The acute onset of symptoms, unilateral 
location, and extreme elevation of intraocular 
pressure that were seen in our patient are clini-
cal findings similar to infectious uveitis syn-
dromes caused by herpesviruses, in which the 
pathogenesis is known to be a direct conse-
quence of active viral replication.14,15 Although 
the relative contribution of lytic viral infection, 
as compared with immunologic reaction to 
EBOV, in the pathogenesis of our patient’s ag-
gressive panuveitis is unclear, the low cycle 
threshold on quantitative RT-PCR assay shows 
that a high burden of viable EBOV was present 
at the time that the patient’s ocular symptoms 
were worsening. Further studies to investigate 
the mechanisms responsible for the ocular per-
sistence of EBOV and the possible presence of 
the virus in other immune-privileged sites (e.g., 
in the central nervous system, gonads, and ar-
ticular cartilage) are warranted.
Few systematic studies have examined post-
EVD sequelae, so the incidence and clinical 
manifestations of post-EVD ocular complica-
tions are uncertain. Of 71 EVD survivors from 
the 1995 Ebola outbreak in the Democratic Re-
public of Congo, 20 were enrolled in a small, 
retrospective study.4 Three of the 20 survivors in 
this limited sample were found to have evidence 
of uveitis (anterior, posterior, or panuveitis) that 
occurred 42 to 72 days after the onset of EVD. 
Data on the incidence of ocular complications 
among survivors of the current West African 
EVD outbreak are also limited. Although 40% of 
participants in a recent survey of 85 EVD survi-
vors in Sierra Leone reported having “eye prob-
lems,” the incidence of uveitis in this cohort is 
unknown.16
In conclusion, our patient’s recovery from 
EVD was complicated by acute anterior uveitis, 
which rapidly evolved into a sight-threatening 
panuveitis with detection of persistent EBOV 
within the eye. This case highlights an important 
complication of EVD with major implications for 
both individual and public health that are im-
mediately relevant to the ongoing West African 
outbreak. It is reassuring that samples of con-
junctivae and tears tested negative for EBOV, a 
finding that supports previous studies suggest-
ing that patients who recover from EVD pose no 
risk of spreading the infection through casual 
Figure 3. Fundus Photograph of the Left Eye 14 Weeks 
after the Onset of Ebola Virus Disease.
Severe vitritis is indicated by the obscuration of the op-
tic nerve and blood vessels.
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contact.3,17 Further studies are needed to assess 
the persistence of EBOV during convalescence, 
to elucidate the mechanisms underlying this 
persistence in ocular and other immune-privi-
leged tissue sites, and to identify effective treat-
ment strategies for the clinical management of 
EVD complications.
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